At Adicet (Nasdaq: ACET), we are defined by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting cancer. Every one of our team members, whether in the lab, manufacturing, or general business role, comes to work every day with the patient in mind. As pioneers in the cell therapy space, we are honored and humbled by the opportunity to put our talents to bear in developing transformative therapies to defeat cancer. We believe that the best way to do this is through discovering and developing allogeneic gamma-delta T cell therapies, a novel type of cell therapy. Adicet has chosen the gamma-delta T cell because it has multiple ways to target and kill cancer cells, which may provide a better chance of achieving complete and durable responses to therapy. Additionally, instead of using cells from the already sick cancer patient, Adicet uses cells from unrelated donors (allogeneic) because they are reliable and readily available allowing us to rapidly and cost-effectively scale production of these medicines and make them available when needed ("off-the-shelf"). Specifically, as a clinical stage biotechnology company we are advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL) to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. To learn more or inquire about joining our team in Boston, MA or Redwood City, CA, please visit http://www.adicetbio.com